Glassman Wealth Services’s Cytokinetics CYTK Stock Holding History

Glassman Wealth Services’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1	Closed	–	–	1234
2019 Q3	$0	Buy	+1	New	+$13	﹤0.01%	1113

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Glassman Wealth Services's CYTK Position: Q4 2019 in Review

Glassman Wealth Services sold out of Cytokinetics (CYTK) in Q4 2019, closing a stake of 1 share.

Glassman Wealth Services first reported a position in CYTK in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 142 funds tracked by Wall St. Rank hold CYTK as of Q4 2019.

Glassman Wealth Services reported no remaining Cytokinetics position as of Q4 2019 after selling out during the quarter.
Glassman Wealth Services sold 1 Cytokinetics share in Q4 2019.
Glassman Wealth Services first reported a position in Cytokinetics in Q3 2019 and held it in 1 quarter.
Glassman Wealth Services's Cytokinetics position peaked at $0 in Q3 2019.
142 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2019.

Based on Glassman Wealth Services's 13F filing for Q4 2019, filed 7 Feb 2020.